Germany and the UK began from a similar place: both accepted cannabis as medicine while surrounding it with enough friction to keep routine access difficult. Their paths have since diverged. Germany has treated reform as an administrative problem as well as a legal one; Britain still behaves as though changing the law in 2018 completed the job.
That difference matters. A medicine can be legal and still remain functionally unavailable when clinicians lack confidence, reimbursement is uncertain and every stage of prescribing feels exceptional.
Reform is measured at the clinic door
Germany's 2024 changes reduced some of the stigma and bureaucracy attached to medical cannabis. They did not create a perfect system, and they did not remove every dispute over reimbursement or prescribing practice. What they did was make the category look more like healthcare and less like an anomaly managed through drug-control policy.
The UK has taken the opposite route. Specialist doctors can prescribe, but NHS access remains rare and most patients who secure treatment do so privately. The result is a system that is lawful on paper yet difficult to encounter through ordinary care.
The useful lesson for Britain
The most important German lesson is not that Britain should copy a single rule. It is that access depends on the machinery around the rule: clinician education, clear professional guidance, workable commissioning and a route for patients that does not rely on chance.
British debate often jumps between two extremes — defending the status quo or calling for wholesale reform. There is a large practical space between them. Better training, clearer treatment pathways and less contradictory regulation could widen access without waiting for an entirely new legal settlement.
Progress still needs scrutiny
Germany continues to face uneven prescribing, cost questions and supply pressures. Rapid commercial growth can also create its own risks if patient safeguards fail to keep pace. Reform should therefore be judged by quality of care, not prescription volume alone.
That is precisely why the comparison is useful. Germany shows that government can remove friction once it decides medical cannabis belongs inside normal healthcare. The UK now needs to decide whether the 2018 change was a symbolic permission or the beginning of a functioning service.
